Primary refractory diffuse large B cell lymphoma in the rituximab era
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference53 articles.
1. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkins lymphoma.;Coiffier;Tumori,2002
2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.;Habermann;J Clin Oncol,2006
3. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.;Pfreundschuh;Lancet Oncol,2011
4. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: a randomised controlled trial (RICOVER-60).;Pfreundschuh;Lancet Oncol,2008
5. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.;Sehn;J Clin Oncol,2005
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Defining primary refractory large B-cell lymphoma;Blood Advances;2024-06-26
2. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy;Experimental Hematology;2024-01
3. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis;Leukemia;2023-12-29
4. A predictive diagnostic model for refractory diffuse large B-cell lymphoma: a single-center retrospective cohort study;2023-12-11
5. Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients;Cancer Management and Research;2020-11
Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3